Healthcare Industry News: Plasmin
News Release - March 24, 2014
BEAT BioTherapeutics Appoints Dr. Sam L. Teichman as Chief Medical OfficerSEATTLE--(Healthcare Sales & Marketing Network)--BEAT BioTherapeutics Corp. (BEATBio) announced today the appointment of Sam L. Teichman, MD, FACC, FESC, FACP, as Chief Medical Officer (CMO) and Director. BEATBio is developing BB-R12, a novel biological therapy with the potential to revolutionize the treatment of heart failure.
Dr. Teichman has nearly 30 years of global clinical research and drug development leadership experience across broad therapeutic areas with a focus on cardiovascular disease and heart failure. As Senior Vice President of R&D and CMO at Corthera, he led the medical effort to develop serelaxin, currently under review for approval by the FDA and EMA, for the treatment of acute heart failure. Dr. Teichman began his biotech career at Genentech where he worked on the development and commercialization of tissue Plasminogen activator (TPA), a breakthrough biological treatment for life threatening arterial blockages. He has over 80 published original articles, reviews and abstracts in peer-reviewed journals.
“Dr. Teichman has led multiple product teams through the Investigation New Drug Application process and into the clinic. His expertise in translational medicine, biologic product development and cardiovascular disease is a perfect complement to our team and comes at an important time for BEATBio. We are delighted to have him join the company,” said Michael Kranda, CEO of BEATBio.
“Cardiovascular disease remains a serious unmet medical need and new therapies are urgently needed. I believe the BEATBio technology has the potential to make a real difference. The scientific foundation and technology behind BB-R12 are as strong as they are novel. I look forward to joining the strong BEATBio team and working to bring this technology to patients,” said Dr. Teichman.
BEATBio is a Seattle, WA-based biotechnology company focused on the development of a novel biological treatment for heart failure. BB-R12 therapy is based on the fundamental discovery that dATP is a superior fuel for cardiac muscle contraction than is ATP. BB-R12 is being developed to treat heart failure by increasing cardiac performance. BEATBio’s founders, from the University of Washington, are recognized experts in cardiovascular biology, muscle physiology and bioengineering, and have received nearly $50MM of NIH funding. BEATBio holds worldwide rights to this technology and used a recently raised $2.9MM seed financing to successfully complete the initial stages of pre-clinical development and manufacturing scale-up. BEATBio assembled a strong team of advisers and contractors that allowed rapid achievement of significant development milestones in 2013. The company is now raising a Series A financing to complete IND-enabling studies and commence Phase I human trials. http://beatbiotherapeutics.com/
Source: BEAT BioTherapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.